Jose J G Marin

List of Publications by Year
in descending order

260	11,858	34105	39675
papers	citations	52 h-index	94 g-index

263	263	263	13087
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Seminars in Liver Disease, 2022, 42, 087-103.	3.6	10
2	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	3.7	119
3	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190.	3.7	11
4	Beneficial effect of ursodeoxycholic acid in patients with acylâ€CoA oxidase 2 (ACOX2) deficiencyâ€“associated hypertransaminasemia. Hepatology, 2022, 76, 1259-1274.	7.3	8
5	Impact of Alternative Splicing Variants on Liver Cancer Biology. Cancers, 2022, 14, 18.	3.7	11
6	New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	9
7	TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation. Journal of Hepatology, 2022, 77, 991-1004.	3.7	22
8	Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies. Cancers, 2022, 14, 3455.	3.7	6
9	Dual Targeting of G9a and DNA Methyltransferaseâ€1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology, 2021, 73, 2380-2396.	7.3	26
10	Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease. Hepatology, 2021, 73, 186-203.	7.3	7
11	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opinion on Investigational Drugs, 2021, 30, 377-388.	4.1	5
12	Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers, 2021, 13, 2358.	3.7	9
13	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. Cell Death and Disease, 2021, 12, 555.	6.3	10
14	Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opinion on Investigational Drugs, 2021, 30, 675-679.	4.1	9
15	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. JHEP Reports, 2021, 3, 100276.	4.9	5
16	STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. Journal of Hepatology, 2021, 74, 1429-1441.	3.7	34
17	Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis. Molecular Therapy - Methods and Clinical Development, 2021, 22, 210-221.	4.1	6
18	Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis. Molecular Metabolism, 2021, 53, 101275.	6.5	22

#	Article	IF	Citations
19	Impact of alternative splicing on mechanisms of resistance to anticancer drugs. Biochemical Pharmacology, 2021, 193, 114810.	4.4	14
20	Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging, 2021, 13, 23416-23434.	3.1	17
21	Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. Cancers, 2021, 13, 5349.	3.7	9
22	Leishmania heme uptake involves LmFLVCRb, a novel porphyrin transporter essential for the parasite. Cellular and Molecular Life Sciences, 2020, 77, 1827-1845.	5.4	22
23	Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters. Biochemical Pharmacology, 2020, 171, 113682.	4.4	7
24	MRP3â€Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. Hepatology, 2020, 72, 949-964.	7.3	19
25	Liver and gastrointestinal cancers. , 2020, , 197-250.		1
26	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059.	6.4	37
27	Multi-Omics Integration Highlights the Role of Ubiquitination in CCl4-Induced Liver Fibrosis. International Journal of Molecular Sciences, 2020, 21, 9043.	4.1	12
28	Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma. Cancers, 2020, 12, 2116.	3.7	35
29	Tuning the intestinal barrier through the neuroendocrine control of ABC pumps expression. Acta Physiologica, 2020, 230, e13544.	3.8	0
30	Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. Cancers, 2020, 12, 2605.	3.7	21
31	Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Cancers, 2020, 12, 3748.	3.7	6
32	Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 211-214.	1.5	6
33	A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers, 2020, 12, 1433.	3.7	20
34	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721.	4.1	63
35	JNK-mediated disruption of bile acid homeostasis promotes intrahepatic cholangiocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16492-16499.	7.1	43
36	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	17.8	1,155

#	Article	IF	Citations
37	Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Cancers, 2020, 12, 1644.	3.7	38
38	Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers, 2020, 12, 1663.	3.7	112
39	Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma. Cells, 2020, 9, 498.	4.1	6
40	Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165687.	3.8	8
41	Role of Genetic Variations in the Hepatic Handling of Drugs. International Journal of Molecular Sciences, 2020, 21, 2884.	4.1	15
42	Biopiracy versus One-World Medicineâ€“From colonial relicts to global collaborative concepts. Phytomedicine, 2019, 53, 319-331.	5.3	13
43	Hepatoprotection of Mentha aquatica L., Lavandula dentata L. and Leonurus cardiaca L.. Antioxidants, 2019, 8, 267.	5.1	13
44	PS-043-Dual targeting of G9a and DNM-methyltransferase-1 for the treatment of experimental cholangiocarcinoma. Journal of Hepatology, 2019, 70, e27-e28.	3.7	1
45	THU-442-Role of drug transporters in the chemoresistance of hepatoblastoma. Journal of Hepatology, 2019, 70, e353.	3.7	0
46	FRI-422-Genetic and pathophysiological factors leading to deficient acyl-CoA oxidase 2 (ACOX2) activity in hepatocytes, an alteration which causes oxidative and endoplasmic reticulum stress in liver cells. Journal of Hepatology, 2019, 70, e579.	3.7	0
47	SAT-425-Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e821-e822.	3.7	0
48	Models for Understanding Resistance to Chemotherapy in Liver Cancer. Cancers, 2019, 11, 1677.	3.7	25
49	Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer. Pharmacogenomics, 2019, 20, 957-970.	1.3	1
50	Chemosensitization of hepatocellular carcinoma cells to sorafenib by Î²-caryophyllene oxide-induced inhibition of ABC export pumps. Archives of Toxicology, 2019, 93, 623-634.	4.2	39
51	What â€œThe Cancer Genome Atlasâ€•database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 577-593.	3.3	23
52	PS-011-New synthetic conjugates of ursodeoxycholic acid inhibit hepatorenal cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2019, 70, e10.	3.7	0
53	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver International, 2019, 39, 43-62.	3.9	54
54	Mechanisms of Anticancer Drug Resistance in Hepatoblastoma. Cancers, 2019, 11, 407.	3.7	36

#	Article	IF	Citations
55	Causes of hOCT1â€Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumorâ€Selective Gene Therapy. Hepatology, 2019, 70, 1246-1261.	7.3	41
56	Evaluation of the promiscuous component of several bacterial export pumps TolC as a biomarker for toxic pollutants in feedstuffs. Chemico-Biological Interactions, 2019, 305, 195-202.	4.0	3
57	Unraveling â€˜The Cancer Genome Atlasâ€™ information on the role of SLC transporters in anticancer drug uptake. Expert Review of Clinical Pharmacology, 2019, 12, 329-341.	3.1	19
58	Epigenetic events involved in organic cation transporter 1â€dependent impaired response of hepatocellular carcinoma to sorafenib. British Journal of Pharmacology, 2019, 176, 787-800.	5.4	39
59	The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis. Hepatology, 2019, 69, 1632-1647.	7.3	42
60	Wntâ€“Î²-catenin signalling in liver development, health and disease. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 121-136.	17.8	341
61	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology, 2019, 70, 547-562.	7.3	112
62	Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma. , 2019, 2, 680-709.		3
63	Dysregulation of autophagy in rat liver with mitochondrial DNA depletion induced by the nucleoside analogue zidovudine. Archives of Toxicology, 2018, 92, 2109-2118.	4.2	8
64	Molecular bases of the poor response of liver cancer to chemotherapy. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 182-192.	1.5	60
65	Chemoresistance and chemosensitization in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1444-1453.	3.8	91
66	MicroRNAâ€506 promotes primary biliary cholangitisâ€“like features in cholangiocytes and immune activation. Hepatology, 2018, 67, 1420-1440.	7.3	72
67	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1468-1477.	3.8	72
68	Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. PLoS ONE, 2018, 13, e0208225.	2.5	3
69	Chemoprotective Role of Vitamin C in Liver Diseases. , 2018, , 139-153.		0
70	Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. Journal of Personalized Medicine, 2018, 8, 14.	2.5	31
71	Role of the placenta in serum autotaxin elevation during maternal cholestasis. American Journal of Physiology - Renal Physiology, 2018, 315, G399-G407.	3.4	9
72	Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2927-2937.	3.8	30

#	Article	IF	Citations
73	Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib. Oncotarget, 2018, 9, 28474-28485.	1.8	12
74	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. Journal of Hepatology, 2017, 67, 72-83.	3.7	81
75	Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. Digestive Diseases, 2017, 35, 275-281.	1.9	8
76	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2017, 66, 1125-1143.	7.3	218
77	Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. Journal of Lipid Research, 2017, 58, 1903-1915.	4.2	18
78	Lactation during cholestasis: Role of ABC proteins in bile acid traffic across the mammary gland. Scientific Reports, 2017, 7, 7475.	3.3	12
79	ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. Journal of Hepatology, 2017, 66, 581-588.	3.7	43
80	Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid. PLoS ONE, 2017, 12, e0176504.	2.5	31
81	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget, 2017, 8, 15846-15857.	1.8	40
82	Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1. Oncotarget, 2017, 8, 34617-34629.	1.8	11
83	Further understanding of mechanisms involved in liver cancer chemoresistance. Hepatoma Research, 2017, 3, .	1.5	5
84	Molecular Bases of Chemoresistance in Cholangiocarcinoma. Current Drug Targets, 2017, 18, 889-900.	2.1	45
85	Effect of pravastatin on the survival of patients with advanced gastric cancer. Oncotarget, 2016, 7, 4379-4384.	1.8	15
86	Liver Cholesterol Overload Aggravates Obstructive Cholestasis by Inducing Oxidative Stress and Premature Death in Mice. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	4.0	26
87	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology, 2016, 63, 1287-1298.	7.3	85
88	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	17.8	964
89	Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach. Pharmacological Research, 2016, 113, 364-375.	7.1	4
90	Lack of mitochondrial DNA impairs chemical hypoxia-induced autophagy in liver tumor cells through ROS-AMPK-ULK1 signaling dysregulation independently of HIF-1Î±. Free Radical Biology and Medicine, 2016, 101, 71-84.	2.9	45

#	Article	IF	Citations
91	Protective role of biliverdin against bile acid-induced oxidative stress in liver cells. Free Radical Biology and Medicine, 2016, 97, 466-477.	2.9	34
92	Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation. Inflammatory Bowel Diseases, 2016, 22, 2382-2389.	1.9	21
93	Mechanisms of Resistance to Chemotherapy in Gastric Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 318-334.	1.7	125
94	Biodetection of potential genotoxic pollutants entering the human food chain through ashes used in livestock diets. Food Chemistry, 2016, 205, 81-88.	8.2	6
95	Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. Blood Reviews, 2016, 30, 55-64.	5.7	39
96	Expanding the Therapeutic Spectrum of Artemisinin: Activity Against Infectious Diseases Beyond Malaria and Novel Pharmaceutical Developments. World Journal of Traditional Chinese Medicine, 2016, 2, 1-23.	1.9	19
97	Bile Acids in Physiology, Pathology and Pharmacology. Current Drug Metabolism, 2015, 17, 4-29.	1.2	131
98	Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP. Annals of Hepatology, 2015, 14, 143-144.	1.5	1
99	The small intestinal mucosa acts as a rutin reservoir to extend flavonoid anti-inflammatory activity in experimental ileitis and colitis. Journal of Functional Foods, 2015, 13, 117-125.	3.4	21
100	Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the motherâ€placentaâ€foetus trio during cholestasis of pregnancy. British Journal of Clinical Pharmacology, 2015, 79, 316-329.	2.4	42
101	Treatment of paediatric cholestasis due to canalicular transport defects: yet another step forward. Gut, 2015, 64, 6-8.	12.1	4
102	Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. Journal of Hepatology, 2015, 63, 952-961.	3.7	56
103	Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT). Journal of Controlled Release, 2015, 216, 93-102.	9.9	30
104	Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP. Annals of Hepatology, 2015, 14, 143-4.	1.5	0
105	The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacologica Sinica, 2014, 35, 1-10.	6.1	44
106	MicroRNAs and cholestatic liver diseases. Current Opinion in Gastroenterology, 2014, 30, 303-309.	2.3	35
107	The effect of acetaminophen on the expression of BCRP in trophoblast cells impairs the placental barrier to bile acids during maternal cholestasis. Toxicology and Applied Pharmacology, 2014, 277, 77-85.	2.8	28
108	Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis. Journal of Molecular Medicine, 2014, 92, 359-372.	3.9	31

#	Article	IF	Citations
109	A GAPDH-Mediated Trans-Nitrosylation Pathway Is Required for Feedback Inhibition of Bile Salt Synthesis in Rat Liver. Gastroenterology, 2014, 147, 1084-1093.	1.3	19
110	Cocarcinogenic Effects of Intrahepatic Bile Acid Accumulation in Cholangiocarcinoma Development. Molecular Cancer Research, 2014, 12, 91-100.	3.4	65
111	SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology, 2014, 59, 1972-1983.	7.3	105
112	Rutin has intestinal antiinflammatory effects in the CD4+ CD62L+ T cell transfer model of colitis. Pharmacological Research, 2014, 90, 48-57.	7.1	85
113	Polycystic liver diseases: advanced insights into the molecular mechanisms. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 750-761.	17.8	80
114	The Expression of Genes Involved in Hepatocellular Carcinoma Chemoresistance Is Affected by Mitochondrial Genome Depletion. Molecular Pharmaceutics, 2014, 11, 1856-1868.	4.6	30
115	Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut, 2014, 63, 1658-1667.	12.1	55
116	Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the expression of the vitamin C transporters SVCT1 and SVCT2. European Journal of Nutrition, 2014, 53, 401-412.	3.9	13
117	Mitochondrial genome depletion in human liver cells abolishes bile acid-induced apoptosis: Role of the Akt/mTOR survival pathway and Bcl-2 family proteins. Free Radical Biology and Medicine, 2013, 61, 218-228.	2.9	21
118	Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. International Immunopharmacology, 2013, 15, 372-380.	3.8	76
119	Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta, 2013, 34, 810-816.	1.5	31
120	Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochemical Pharmacology, 2013, 86, 926-939.	4.4	88
121	FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver. Biochemical Pharmacology, 2013, 85, 829-838.	4.4	25
122	Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut, 2013, 62, 899-910.	12.1	163
123	Protective effects of phenolic constituents from Cytisus multiflorus, Lamium album L. and Thymus citriodorus on liver cells. Journal of Functional Foods, 2013, 5, 1170-1179.	3.4	34
124	Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorganic and Medicinal Chemistry, 2013, 21, 4432-4441.	3.0	74
125	Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 2212-2219.	4.1	46
126	Role of the Plasma Membrane Transporter of Organic Cations OCT1 and Its Genetic Variants in Modern Liver Pharmacology. BioMed Research International, 2013, 2013, 1-13.	1.9	46

#	Article	IF	Citations
127	Expression ofSLC22A1variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology, 2013, 58, 1065-1073.	7.3	124
128	Maternal cholestasis during pregnancy programs metabolic disease in offspring. Journal of Clinical Investigation, 2013, 123, 3172-3181.	8.2	92
129	Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs. Current Cancer Drug Targets, 2012, 12, 402-438.	1.6	57
130	Characterization of the Role of ABCG2 as a Bile Acid Transporter in Liver and Placenta. Molecular Pharmacology, 2012, 81, 273-283.	2.3	63
131	Plasma Membrane Transporters in Modern Liver Pharmacology. Scientifica, 2012, 2012, 1-15.	1.7	15
132	MicroRNAs in biliary diseases. World Journal of Gastroenterology, 2012, 18, 6189.	3.3	30
133	Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice. Journal of Hepatology, 2012, 56, 367-373.	3.7	43
134	Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metabolism Reviews, 2012, 44, 148-172.	3.6	117
135	ABCC2 is involved in the hepatocyte perinuclear barrier for small organic compounds. Biochemical Pharmacology, 2012, 84, 1651-1659.	4.4	5
136	Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy. Pharmacological Research, 2012, 66, 419-427.	7.1	9
137	Cisplatin-Induced Chemoresistance in Colon Cancer Cells Involves FXR-Dependent and FXR-Independent Up-Regulation of ABC Proteins. Molecular Pharmaceutics, 2012, 9, 2565-2576.	4.6	55
138	No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors. Molecular Pharmaceutics, 2012, 9, 1693-1704.	4.6	73
139	Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology, 2012, 425, 31-39.	2.4	80
140	Diversity of Pharmacological Properties in Chinese and European Medicinal Plants: Cytotoxicity, Antiviral and Antitrypanosomal Screening of 82 Herbal Drugs. Diversity, 2011, 3, 547-580.	1.7	32
141	Nitric oxide mimics transcriptional and post-translational regulation during Î±-Tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes. Journal of Hepatology, 2011, 55, 133-144.	3.7	32
142	Mitochondrial genome depletion dysregulates bile acidâ€•and paracetamolâ€•induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells. British Journal of Pharmacology, 2011, 162, 1686-1699.	5.4	32
143	Characterisation of the nuclear receptors FXR, PXR and CAR in normal and cholestatic placenta. Placenta, 2011, 32, 535-537.	1.5	21
144	Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. Biochemical Pharmacology, 2011, 81, 244-250.	4.4	20

#	Article	IF	Citations
145	Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 740-750.	2.6	19
146	Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases. British Journal of Nutrition, 2011, 106, 1814-1825.	2.3	28
147	A homozygous nonsense mutation (c.214C->A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis. Journal of Medical Genetics, 2011, 48, 219-225.	3.2	45
148	Further Characterization of the Electrogenicity and pH Sensitivity of the Human Organic Anion-Transporting Polypeptides OATP1B1 and OATP1B3. Molecular Pharmacology, 2011, 79, 596-607.	2.3	39
149	Strategies for Overcoming Chemotherapy Resistance in Enterohepatic Tumours. Current Molecular Medicine, 2010, 10, 467-485.	1.3	15
150	Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology, 2010, 52, 667-677.	7.3	20
151	Inhibition of Na+-Taurocholate Co-transporting Polypeptide-mediated Bile Acid Transport by Cholestatic Sulfated Progesterone Metabolites. Journal of Biological Chemistry, 2010, 285, 16504-16512.	3.4	54
152	Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment. Current Medicinal Chemistry, 2010, 17, 709-740.	2.4	58
153	Overview of the Molecular Bases of Resistance to Chemotherapy in Liver and Gastrointestinal Tumours. Current Molecular Medicine, 2009, 9, 1108-1129.	1.3	33
154	Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 162-184.	1.7	38
155	Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. Toxicology and Applied Pharmacology, 2009, 239, 21-28.	2.8	16
156	In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives. Toxicology and Applied Pharmacology, 2009, 239, 13-20.	2.8	15
157	Foetal â€˜flatâ€™ bile acids reappear during human liver regeneration after surgery. European Journal of Clinical Investigation, 2009, 39, 58-64.	3.4	11
158	Bile acids: Chemistry, physiology, and pathophysiology. World Journal of Gastroenterology, 2009, 15, 804.	3.3	427
159	Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs. Frontiers in Bioscience - Landmark, 2009, Volume, 4257.	3.0	10
160	Excretion of biliary compounds during intrauterine life. World Journal of Gastroenterology, 2009, 15, 817.	3.3	55
161	Molecular bases of the fetal liverâ€“placentaâ€“maternal liver excretory pathway for cholephilic compounds. Liver International, 2008, 28, 435-454.	3.9	24
162	Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal unit in cholestasis during pregnancy. Toxicology and Applied Pharmacology, 2008, 232, 327-336.	2.8	13

#	Article	IF	Citations
163	The Antiviral Activities of Artemisinin and Artesunate. Clinical Infectious Diseases, 2008, 47, 804-811.	5.8	425
164	Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Reviews in Molecular Medicine, 2008, 10, e9.	3.9	80
165	Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes. American Journal of Physiology - Renal Physiology, 2008, 295, G54-G62.	3.4	9
166	How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion. World Journal of Gastroenterology, 2008, 14, 5617.	3.3	5
167	Effect of Cantharidin, Cephalotaxine and Homoharringtonine on â€in vitroâ€•Models of Hepatitis B Virus (HBV) and Bovine Viral Diarrhoea Virus (BVDV) Replication. Planta Medica, 2007, 73, 552-558.	1.3	33
168	Ontogenic development-associated changes in the expression of genes involved in rat bile acid homeostasis. Journal of Lipid Research, 2007, 48, 1362-1370.	4.2	21
169	Characterization of WIF-B9/R cells as an in vitro model with hepatocyte-like polarity and enhanced expression of canalicular ABC transporters involved in phase III of hepatic detoxification. Toxicology, 2007, 232, 24-36.	4.2	5
170	Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. Bioorganic and Medicinal Chemistry, 2007, 15, 2359-2367.	3.0	15
171	Multiple protective effects of melatonin against maternal cholestasis-induced oxidative stress and apoptosis in the rat fetal liver?placenta?maternal liver trio. Journal of Pineal Research, 2007, 43, 130-139.	7.4	12
172	Inhibition of the intestinal absorption of bile acids using cationic derivatives: Mechanism and repercussions. Biochemical Pharmacology, 2007, 73, 394-404.	4.4	18
173	Novel bile acid derivatives (BANBs) with cytostatic activity obtained by conjugation of their side chain with nitrogenated bases. Biochemical Pharmacology, 2007, 73, 1394-1404.	4.4	21
174	Expression in Human Trophoblast and Choriocarcinoma Cell Lines, BeWo, Jeg-3 and JAr of Genes Involved in the Hepatobiliary-like Excretory Function of the Placenta. Placenta, 2007, 28, 107-117.	1.5	102
175	Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3â^'1 and Can 10. Cell and Tissue Research, 2007, 330, 447-460.	2.9	15
176	Cholestasis During Pregnancy: Aetiopathogenesis, Foetal-Maternal Repercussions and Pharmacological Treatments. Current Women's Health Reviews, 2007, 3, 235-247.	0.2	1
177	Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sciences, 2006, 79, 1014-1019.	4.3	8
178	Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. Journal of Hepatology, 2006, 44, 1150-1157.	3.7	120
179	Maternal ethanol consumption during pregnancy enhances bile acid-induced oxidative stress and apoptosis in fetal rat liver. Toxicology, 2006, 225, 183-194.	4.2	33
180	Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochemical Pharmacology, 2006, 72, 729-738.	4.4	74

#	Article	IF	Citations
181	Maternal cholestasis induces placental oxidative stress and apoptosis. Protective effect of ursodeoxycholic acid. Placenta, 2006, 27, 34-41.	1.5	80
182	Antiviral Effect of Artemisinin from Artemisia annua against a Model Member of the Flaviviridae Family, the Bovine Viral Diarrhoea Virus (BVDV). Planta Medica, 2006, 72, 1169-1174.	1.3	124
183	Excretion of fetal biliverdin by the rat placenta-maternal liver tandem. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R749-R756.	1.8	11
184	OATP8/1B3-mediated Cotransport of Bile Acids and Glutathione. Journal of Biological Chemistry, 2006, 281, 30326-30335.	3.4	78
185	Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clinical Science, 2005, 109, 199-207.	4.3	13
186	Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 547-554.	2.8	31
187	Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an â€œin vitroâ€• replicative system. Antiviral Research, 2005, 68, 75-83.	4.1	198
188	Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Annals of Hepatology, 2005, 4, 70-76.	1.5	29
189	Long-Term Effect of Treating Pregnant Rats with Ursodeoxycholic Acid on the Congenital Impairment of Bile Secretion Induced in the Pups by Maternal Cholestasis. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 751-758.	2.5	17
190	Proapoptotic Effect on Normal and Tumor Intestinal Cells of Cytostatic Drugs with Enterohepatic Organotropism. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 24-35.	2.5	21
191	Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. Journal of Hepatology, 2005, 43, 324-332.	3.7	68
192	Transient changes in the expression pattern of key enzymes for bile acid synthesis during rat liver regeneration. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1734, 127-135.	2.4	11
193	Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Annals of Hepatology, 2005, 4, 70-6.	1.5	8
194	A Review on the Molecular Mechanisms Involved in the Placental Barrier for Drugs. Current Drug Delivery, 2004, 1, 275-289.	1.6	30
195	Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R1505-R1516.	1.8	57
196	The Hepatobiliary-like Excretory Function of the Placenta. A Review. Placenta, 2003, 24, 431-438.	1.5	42
197	Excretion of Foetal Bilirubin by the Rat Placentaâ€“Maternal Liver Tandem. Placenta, 2003, 24, 462-472.	1.5	15
198	Effect of maternal cholestasis on the kinetics of bile acid transport across the canalicular membrane of infant rat livers. International Journal of Experimental Pathology, 2003, 78, 383-390.	1.3	6

#	Article	IF	Citations
199	Sensitivity of bile acid transport by organic anion-transporting polypeptides to intracellular pH. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1611, 249-257.	2.6	19
200	Effect of Ursodeoxycholic Acid on the Impairment Induced by Maternal Cholestasis in the Rat Placenta-Maternal Liver Tandem Excretory Pathway. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 515-524.	2.5	57
201	Physiological characteristics of allo-cholic acid. Journal of Lipid Research, 2003, 44, 84-92.	4.2	19
202	Usefulness of Liposomes Loaded with Cytostatic Bile Acid Derivatives to Circumvent Chemotherapy Resistance of Enterohepatic Tumors. Molecular Pharmacology, 2003, 63, 742-750.	2.3	40
203	Effect of maternal obstructive cholestasis during pregnancy on the biliary transport of horseradish peroxidase in the rat offspring. Clinical Science, 2003, 105, 347-353.	4.3	6
204	Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochemical Journal, 2003, 371, 897-905.	3.7	160
205	Carriers Involved in Targeting the Cytostatic Bile Acid-Cisplatin Derivativescis-Diammine-chloro-cholylglycinate-platinum(II) andcis-Diammine-bisursodeoxycholate-platinum(II) toward Liver Cells. Molecular Pharmacology, 2002, 61, 853-860.	2.3	130
206	Evidence for Dual Effects of DNA-Reactive Bile Acid Derivatives (Bamets) on Hepatitis B Virus Life Cycle in anIn VitroReplicative System. Antiviral Chemistry and Chemotherapy, 2002, 13, 371-380.	0.6	8
207	Changes in the pattern of bile acids in the nuclei of rat liver cells during hepatocarcinogenesis. Clinical Science, 2002, 102, 143.	4.3	10
208	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587-593.	4.3	48
209	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587.	4.3	25
210	Changes in the pool of bile acids in hepatocyte nuclei during rat liver regeneration. Journal of Hepatology, 2002, 36, 534-542.	3.7	41
211	Relationship Between Tumor Cell Load and Sensitivity to the Cytostatic Effect of Two Novel Platinum-bile Acid Complexes, Bamet-D3 and Bamet-UD2. Journal of Drug Targeting, 2002, 10, 397-404.	4.4	7
212	Evidence for Carrier-mediated Transport of Unconjugated Bilirubin Across Plasma Membrane Vesicles from Human Placental Trophoblast. Placenta, 2002, 23, 527-535.	1.5	44
213	Chronic renal failure-induced changes in serum and urine bile acid profiles. Digestive Diseases and Sciences, 2002, 47, 2398-2406.	2.3	35
214	Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clinical Science, 2002, 102, 587-93.	4.3	15
215	Predominance of human versus rat phenotype in the metabolic pathways for bile acid synthesis by hybrid WIF-B9 cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2001, 1534, 45-55.	2.4	12
216	Liver Organotropism and Biotransformation of a Novel Platinum-Ursodeoxycholate Derivative, Bamet-UD2, with Enhanced Antitumour Activity. Journal of Drug Targeting, 2001, 9, 185-200.	4.4	17

#	Article	IF	Citations
217	Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clinical Science, 2001, 100, 499-508.	4.3	14
218	Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma. Clinical Science, 2001, 100, 499.	4.3	25
219	Overcoming cisplatin resistancein vitro by a free and liposome-encapsulated bile acid derivative: BAMET-R2. International Journal of Cancer, 2000, 88, 287-292.	5.1	27
220	Effect of maternal cholestasis on bile acid transfer across the rat placentaâ€“maternal liver tandem. Hepatology, 2000, 31, 975-983.	7.3	53
221	Structural Characterization, Kinetic Studies, and in Vitro Biological Activity of Newcis-Diamminebis-cholylglycinate(O,Oâ€˜) Pt(II) andcis-Diamminebis-ursodeoxycholate(O,Oâ€˜) Pt(II) Complexes. Bioconjugate Chemistry, 2000, 11, 167-174.	3.6	37
222	Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1500, 153-160.	3.8	52
223	Bile acid secretion during rat liver carcinogenesis. Life Sciences, 2000, 66, 1085-1095.	4.3	16
224	Overcoming cisplatin resistance in vitro by a free and liposomeâ€encapsulated bile acid derivative: BAMETâ€R2. International Journal of Cancer, 2000, 88, 287-292.	5.1	1
225	Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. Gut, 1999, 45, 446-452.	12.1	62
226	Synthesis and characterization of sodium cis-dichlorochenodeoxycholylglycinato(O,N) platinum(II)–cytostatic activity. BioMetals, 1999, 12, 283-290.	4.1	12
227	Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). Journal of Controlled Release, 1999, 57, 161-169.	9.9	18
228	Further evidence of the usefulness of bile acids as molecules for shuttling cytostatic drugs toward liver tumors. Journal of Hepatology, 1999, 31, 521-528.	3.7	41
229	DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2. International Journal of Cancer, 1998, 78, 346-352.	5.1	27
230	Fetal excretion of the fluorescent bile acid derivative cholylglycylamido-fluorescein (FITC-GC) by the rat placenta-maternal liver tandem. Placenta, 1998, 19, 119-126.	1.5	9
231	Transient enterohepatic circulation and enhanced biliary versus urinary excretion of the cytostatic drug bischolylglycinate-chloroplatinum(II) (Bamet-H2)1Part of this work has appeared in abstract form in Hepatology (1996) 24:372A:982.1. International Journal of Pharmaceutics, 1998, 172, 79-88.	5.2	3
232	Enhanced bile formation induced by experimental dicrocoeliosis in the hamster. Life Sciences, 1998, 63, 1963-1974.	4.3	4
233	Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. Journal of Hepatology, 1998, 28, 829-839.	3.7	114
234	Rat liver transport and biotransformation of a cytostatic complex of bis-cholylglycinate and platinum (II). Journal of Hepatology, 1998, 28, 417-425.	3.7	21

#	Article	IF	Citations
235	Transport and biotransformation of the new cytostatic complex cis-diammineplatinum(II)-chlorocholylglycinate (Bamet-R2) by the rat liver. Journal of Lipid Research, 1998, 39, 1792-1798.	4.2	22
236	In vitro test to determine the effect of cytostatic drugs on co-cultured rat hepatocytes and hepatoma cells. International Journal of Experimental Pathology, 1998, 79, 109-115.	1.3	4
237	Synthesis and Characterization of the New Cytostatic Complexcis-Diammineplatinum(II)â^'Chlorocholylglycinate. Bioconjugate Chemistry, 1997, 8, 453-458.	3.6	41
238	Bile acid secretion during synchronized rat liver regeneration1This study was supported in part by grants SAF94-0693 and SAF96-0146 from the Comision Interministerial Cientifica y Tecnica and grants SA21/96 and SA19/97 from the Junta de Castilla y Leon, Spain.1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1997, 1362, 56-66.	3.8	22
239	Effect of Bile Acids on Hepatobiliary Transport of Cisplatin by Perfused Rat Liver. Basic and Clinical Pharmacology and Toxicology, 1997, 80, 111-117.	0.0	2
240	Bile secretion by the rat liver during synchronized regeneration. International Journal of Experimental Pathology, 1997, 78, 109-116.	1.3	12
241	Effect of maternal cholestasis on biliary lipid and bile acid secretion in the infant rat. Hepatology, 1997, 26, 527-536.	7.3	18
242	Evidence for dual effect of bile acids on thymidine anabolism and catabolism by the regenerating rat liver. Biochimica Et Biophysica Acta - General Subjects, 1996, 1289, 136-144.	2.4	2
243	Role of rate-limiting enzymes of nucleotide metabolism in taurocholate-induced DNA synthesis inhibition. Journal of Hepatology, 1996, 25, 191-199.	3.7	5
244	Reversible impairment of neonatal hepatobiliary function by maternal cholestasis. Hepatology, 1996, 23, 1208-1217.	7.3	42
245	Relationship between Bile Acid Transplacental Gradients and Transport across the Fetal-Facing Plasma Membrane of the Human Trophoblast. Pediatric Research, 1995, 38, 156-163.	2.3	32
246	Bile acidâ€“induced modifications in DNA synthesis by the regenerating perfused rat liver. Hepatology, 1993, 18, 1182-1192.	7.3	17
247	Influence of hydroxylation and conjugation in cross-inhibition of bile acid transport across the human trophoblast basal membrane. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1151, 28-34.	2.6	11
248	Effect of insulin and glucose load on bile lactate secretion by the isolated rat liver. Role of hepatic parenchyma heterogeneity. Biochimica Et Biophysica Acta - General Subjects, 1993, 1158, 8-14.	2.4	1
249	Bile acid-induced modifications in DNA synthesis by the regenerating perfused rat liver,. Hepatology, 1993, 18, 1182-1192.	7.3	1
250	Substrate-specific differences in the rate of bile acid carrier reorientation: studies on human placental basal vesicles. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1111, 139-141.	2.6	0
251	Plasma membrane-bound carbonic anhydrase activity in the regenerating rat liver. Biochimica Et Biophysica Acta - Biomembranes, 1991, 1061, 9-14.	2.6	7
252	Hyperglycemia-induced cholestasis in the isolated perfused rat liver. Hepatology, 1991, 14, 184-191.	7.3	17

#	Article	IF	Citations
253	Bile acid transport by basal membrane vesicles of human term placental trophoblast. Gastroenterology, 1990, 99, 1431-1438.	1.3	48
254	Influence of backward perfusion on ursodeoxycholate-induced choleresis in isolated in situ rat liver. Journal of Hepatology, 1990, 11, 165-171.	3.7	39
255	Effect of streptozotocin-induced diabetes on sex differences in biliary lipid secretion in the rat. Lipids and Lipid Metabolism, 1990, 1043, 106-112.	2.6	6
256	Diabetes-Induced cholestasis in the rat: Possible role of hyperglycemia and hypoinsulinemia. Hepatology, 1988, 8, 332-340.	7.3	33
257	Evidence for the presence of carbonic anhydrase in the plasma membrane of rat hepatocytes. Biochimica Et Biophysica Acta - Biomembranes, 1988, 945, 17-22.	2.6	14
258	Influence of Dehydrocholate on Bilirubin Transport into Bile in the Rat. Digestion, 1986, 33, 80-88.	2.3	7
259	Use of Thermal Fogs of Bioresmethrin and Cismethrin for Control of Periplaneta Americana (Insecta:) Tj ETQq1 1 0.784314 rgBT /Over	1.8	6
260	Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International, 0, , .	1.3	0